Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | September 14, 2016 |
| Target | Vitae Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Allergan |
| Deal Type | Add-on Acquisition |
| Deal Value | 639M USD |
| Advisor(s) | J.P. Morgan Securities (Financial) Gunderson Dettmer (Legal) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1956 |
| Sector | Life Science |
| Employees | 31,200 |
| Revenue | 15.8B USD (2018) |
Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.
| Deal Context for Buyer | # |
|---|---|
| Overall | 28 of 38 |
| Sector: Life Science | 18 of 23 |
| Type: Add-on Acquisition | 22 of 31 |
| State: Pennsylvania | 1 of 1 |
| Country: United States | 19 of 27 |
| Year: 2016 | 5 of 9 |
| Size (of disclosed) | 11 of 25 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-09-06 |
RetroSense Therapeutics
Ann Arbor, Michigan, United States RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. There are currently no FDA-approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic. |
Buy | $60M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-09-20 |
Akarna Therapeutics
Cambridge, United Kingdom Akarna Therapeutics Ltd. is a bio-pharmaceutical company, that develops novel small molecule therapeutics that target inflammatory and fibrotic diseases. |
Buy | $50M |
